Photo: Female researcher using a machine in the lab


Ocrelizumab was licensed by the European Medicines Agency in January 2018.

>> Read more about this licence

In March 2017 it was approved by the US Food and Drug Administration (FDA) as a treatment for both relapsing and primary progressive MS.

Earlier this year in June 2018  NICE approved it for treating relapsing MS. We're waiting for a final decision for advanced  progressive MS.

Ocrelizumab is an intravenous infusion treatment that has been developed by Roche.

Current phase of trial: Licensed

Type of MS: primary progressive and relapsing MS

Find out more about ocrelizumab